LL-37

Quick Summary

• What it is: LL-37 is the only human cathelicidin-derived antimicrobial peptide (AMP), produced primarily by epithelial cells, neutrophils, and keratinocytes as part of the innate immune system.
• Regulatory status: Removed from FDA Category 2 on April 15, 2026. Final 503A Bulks List placement pending July 23–24 PCAC meeting. Currently available through licensed 503A compounding pharmacies with valid prescription.
• Research stage: Preclinical and early clinical. LL-37 has been studied in wound healing, antimicrobial applications, and immune modulation, with approximately 2,500 PubMed-indexed publications as of May 2026.
• Key distinction: Unlike BPC-157 or TB-500 (synthetic analogues), LL-37 is an endogenous human peptide — the body produces it naturally — which gives it a different safety profile in terms of immunogenicity.

What Is LL-37?

LL-37 is a 37-amino acid amphipathic alpha-helical peptide encoded by the CAMP (cathelicidin antimicrobial peptide) gene. It is the only member of the cathelicidin family of antimicrobial peptides expressed in humans (other mammals have multiple cathelicidins). The peptide is generated by proteolytic cleavage of the hCAP-18 precursor protein.

LL-37 serves multiple functions in the innate immune system:

• Direct antimicrobial activity: Disrupts bacterial, fungal, and enveloped viral membranes through electrostatic interaction with negatively charged microbial lipid bilayers.
• Immune modulation: Chemoattracts neutrophils, monocytes, and T-cells; modulates dendritic cell differentiation; suppresses pro-inflammatory cytokine release under certain conditions.
• Wound healing: Promotes re-epithelialization, angiogenesis, and fibroblast migration at wound sites.
• Biofilm disruption: Shown to inhibit and disrupt bacterial biofilms at sub-antimicrobial concentrations, a property of interest for chronic wound and implant-associated infections.

Research Overview

Antimicrobial Activity

LL-37 exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. A 2024 systematic review in Frontiers in Microbiology found LL-37 effective against MRSA, Pseudomonas aeruginosa, and Acinetobacter baumannii at micromolar concentrations. The peptide’s mechanism — membrane disruption rather than receptor-specific inhibition — makes conventional resistance development less likely.

A May 2026 Europe PMC-indexed study examined molecular interaction modes of LL-37 and its mutants, identifying structural determinants of antimicrobial activity that could inform synthetic analogue design.

Wound Healing

The cathelicidin peptide LL-37 plays a central role in cutaneous wound repair. It stimulates keratinocyte migration and proliferation through transactivation of the epidermal growth factor receptor (EGFR). A March 2026 study in Frontiers in Pharmacology explored the role of LL-37 and ceragenins (synthetic cationic steroid antibiotics) in wound healing processes, reporting improved re-epithelialization rates in ex vivo human skin models.

Clinical interest focuses on chronic wounds (diabetic ulcers, venous stasis ulcers) where endogenous LL-37 levels are often suppressed by the inflammatory microenvironment. Topical LL-37 formulations have been explored as a therapeutic strategy to restore healing capacity in these settings.

Cancer Biology

LL-37 has a dual role in cancer biology that complicates its therapeutic profile. A December 2025 study found increased cathelicidin LL-37 colonic expression associated with tumor progression in colorectal cancer. Conversely, the peptide has been shown to exhibit anti-tumor activity against certain cancer cell lines through membrane disruption and immune activation.

A March 2026 study examined LL-37’s role in cancer cell migration control, highlighting the context-dependent nature of its effects. This dual activity — pro- and anti-tumorigenic depending on tissue microenvironment — is an active area of investigation.

Neutrophil Extracellular Traps

May 2026 research demonstrated that LL-37 compacts nucleic acids and alters neutrophil extracellular trap (NET) structure. This finding has implications for both innate immune function and autoimmune conditions where NET dysregulation is implicated, such as systemic lupus erythematosus and rheumatoid arthritis.

Regulatory Status

Pre-April 2026

LL-37 was included in the FDA’s April 2023 enforcement action placing 14 peptides in Category 2 (significant safety concern), effectively prohibiting compounding pharmacies from bulk production. The FDA cited: (1) lack of FDA-approved drug products containing LL-37, (2) insufficient published evidence of safety and efficacy for clinical use, and (3) concerns about unregulated distribution through research chemical suppliers.

April 15, 2026 Reclassification

The FDA removed LL-37 from Category 2 along with 11 other peptides (GHK-Cu was already in Category 1). This reclassification, announced during the agency’s response to an industry citizen petition, allows 503A compounding pharmacies to produce LL-37 under valid patient-specific prescriptions. The FDA stated the action was based on a “refined evaluation of the scientific evidence and public health considerations.”

July 2026 PCAC Meeting

The Pharmacy Compounding Advisory Committee will review LL-37 at its July 23–24, 2026 meeting. The committee will recommend whether LL-37 should be placed on the 503A Bulks List — the permanent framework for compounding ingredients not otherwise included in FDA-approved drug products. The outcome will determine whether compounding pharmacies can continue producing LL-37 after the interim reclassification period ends.

Post-PCAC Scenarios

• Placed on 503A Bulks List: LL-37 becomes a permanently available compounding ingredient under the standard 503A framework. Compounding pharmacies may produce it indefinitely under valid prescriptions.
• Not placed on Bulks List: LL-37 returns to Category 2 status. Compounding would be prohibited except for individual patient prescriptions with documented medical need (essentially reverting to the pre-April 15 framework).

Safety Profile

LL-37’s status as an endogenous human peptide provides a theoretical safety advantage over synthetic analogues — the human immune system is unlikely to mount an adaptive immune response against a self-peptide. However, several safety considerations warrant attention:

• Pro-inflammatory effects at high concentrations: LL-37 can trigger mast cell degranulation and enhance endotoxin-mediated inflammation at supraphysiological doses.
• Cytotoxicity at high doses: Like all antimicrobial peptides, LL-37 exhibits concentration-dependent cytotoxicity against mammalian cells, though the therapeutic index appears favorable in preclinical models.
• Cancer context-dependence: As noted above, LL-37’s role in cancer progression is tissue-dependent. Patients with active malignancies or cancer risk factors should be evaluated cautiously.
• Limited human clinical data: No FDA-approved LL-37 drug product exists. Human data come from small observational studies and case reports, primarily in wound healing contexts.

Key Differences from Other Reclassified Peptides

Feature	LL-37	BPC-157	TB-500
Origin	Endogenous human	Synthetic (based on body protein)	Synthetic (thymosin beta-4 fragment)
Primary mechanism	Antimicrobial + immune modulation	Angiogenesis + GI healing	Actin binding + cell migration
Research volume	~2,500 papers	~1,200 papers	~800 papers
Human clinical data	Limited (topical wound studies)	Minimal	Minimal
Cancer signal	Dual (pro/anti-tumorigenic)	Mixed	Mixed

Bottom Line

LL-37 holds a unique position among the reclassified peptides: as the only endogenous human antimicrobial peptide on the list, its scientific foundation is distinct from the synthetic analogues. The July PCAC decision will clarify whether the FDA agrees that LL-37’s clinical evidence base supports permanent compounding access.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.